OSE Immunotherapeutics Reports Positive Topline Results From Combi-TED Phase 2 Trial
OSE Immunotherapeutics reported positive topline results from its randomized Phase 2 Combi-TED trial of Tedopi in metastatic non-small cell lung cancer.
OSE Immunotherapeutics reported positive topline results from its randomized Phase 2 Combi-TED trial of Tedopi in metastatic non-small cell lung cancer.